Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection

MLA

Song Dong, PhD, et al. “Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection.” JTO Clinical and Research Reports, vol. 6, no. 1, Jan. 2025. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2024.100758.

APA

Song Dong, P., Bingfa Yan, P., Si-Yang Liu, P., Xuan Gao, P., Hui-Zhao Hong, M., Hong-Ji Li, M., Wei Gao, P., Hong-Hong Yan, P., Si-Yang Maggie Liu, P., Hai-Yan Tu, P., Yi Pan, P., Qing Zhou, P., Xue-Ning Yang, P., Xue-Feng Xia, P., Xin Yi, P., Wen-Zhao Zhong, P., Yi-Long Wu, M., & Jia-Tao Zhang, P. (2025). Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection. JTO Clinical and Research Reports, 6(1). https://doi.org/10.1016/j.jtocrr.2024.100758

Chicago

Song Dong, PhD, PhD Bingfa Yan, PhD Si-Yang Liu, PhD Xuan Gao, Md Hui-Zhao Hong, Md Hong-Ji Li, PhD Wei Gao, et al. 2025. “Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection.” JTO Clinical and Research Reports 6 (1). doi:10.1016/j.jtocrr.2024.100758.